(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 1 879 591 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
04.04.2012 Bulletin 2012/14

(45) Date of publication and mention of the grant of the patent:
25.01.2012 Bulletin 2012/04

(21) Application number: **06724715.5**

(22) Date of filing: **04.05.2006**

(51) Int Cl.:
A61K 31/55 *(2006.01)* ***C07D 471/14*** *(2006.01)*
A61P 3/10 *(2006.01)* ***A61P 25/28*** *(2006.01)*
A61K 45/00 *(2006.01)*

(86) International application number:
PCT/EP2006/004186

(87) International publication number:
WO 2006/117221 (09.11.2006 Gazette 2006/45)

(54) **USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS**

VERWENDUNG VON AZAPAULLONEN ZUR VORBEUGUNG UND BEHANDLUNG PANKREATISCHER AUTOIMMUNKRANKHEITEN

UTILISATION D'AZAPAULLONES POUR LA PREVENTION ET LE TRAITEMENT DE TROUBLES AUTO-IMMUNES DU PANCREAS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: **04.05.2005 EP 05009846**
22.07.2005 EP 05015986
24.10.2005 EP 05023168
23.01.2006 EP 06001327

(43) Date of publication of application:
23.01.2008 Bulletin 2008/04

(73) Proprietors:
- **DeveloGen Aktiengesellschaft**
  37079 Göttingen (DE)
- **Technische Universität Carolo-Wilhelmina zu Braunschweig**
  38106 Braunschweig (DE)

(72) Inventors:
- **MUSSMANN, Rainer**
  4312 Magden (CH)
- **KUNICK, Conrad**
  21149 Hamburg (DE)
- **STUKENBROCK, Hendrik**
  48147 Münster (DE)
- **GEESE, Marcus**
  37073 Göttingen (DE)
- **KEGEL, Simone**
  37170 Uslar (DE)
- **BURK, Ulrike**
  37073 Göttingen (DE)

(74) Representative: **Weiss, Wolfgang et al**
Weickmann & Weickmann
Patentanwälte
Postfach 86 08 20
81635 München (DE)

(56) References cited:
EP-A- 1 477 490
WO-A-02/086107
WO-A-03/011843
WO-A-2005/086814
WO-A-2005/104836
US-A1- 2003 181 439
US-A1- 2005 090 483

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Printed by Jouve, 75001 PARIS (FR)

(Cont. next page)

- MEIJER L ET AL: "Pharmacological inhibitors of glycogen synthase kinase 3" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 25, no. 9, September 2004 (2004-09), pages 471-480, XP004552644 ISSN: 0165-6147
- COHEN P ET AL: "GSK3 inhibitors: Development and therapeutic potential" NATURE REVIEWS DRUG DISCOVERY 2004 UNITED KINGDOM, vol. 3, no. 6, 2004, pages 479-487, XP002357670 ISSN: 1474-1776 cited in the application
- LEOST M ET AL: "Paullones are potent inhibitors of glycogen synthase kinase-3.beta. and cyclin-dependent kinase 5/p25" EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 267, no. 19, 2000, pages 5983-5994, XP002384290 ISSN: 0014-2956
- OGAWA NORIHIKO ET AL: "Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4" DIABETES, vol. 53, no. 7, July 2004 (2004-07), pages 1700-1705, XP002390322 ISSN: 0012-1797 cited in the application
- MARTINEZ A ET AL: "GLYCOGEN SYNTHASE KINASE 3 (GSK-3) INHIBITORS AS NEW PROMISING DRUGS FOR DIABETES, NEURODEGENERATION, CANCER, AND INFLAMMATION", MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 22, no. 4, 1 January 2002 (2002-01-01), pages 373-384, XP009058328, ISSN: 0198-6325, DOI: DOI: 10.1002/MED.10011